Abstract:Triple-negative breast cancer (TNBC) is regarded as the deadliest subtype of breast cancer because of its high heterogeneity, aggressiveness, and limited treatment options. Toxoflavin has been reported to possess antitumor activity. In this study, a series of toxoflavin analogs were synthesized, among which D43 displayed a significant dose-dependent inhibitory effect on the proliferation of TNBC cells (MDA-MB-231 and HCC1806). Additionally, D43 inhibited DNA synthesis in TNBC cells, leading to cell cycle arrest at the G2/M phase. Furthermore, D43 consistently promoted intracellular ROS generation, induced DNA damage, and resulted in apoptosis in TNBC cells. These effects could be reversed by N-acetylcysteine. Moreover, D43 significantly inhibited the growth of breast cancer patient-derived organoids and xenografts with a favorable biosafety profile. In conclusion, D43 is a potent anticancer agent that elicits significant antiproliferation, oxidative stress, apoptosis, and DNA damage effects in TNBC cells, and D43 holds promise as a potential candidate for the treatment of TNBC.

What problem does this paper attempt to address?

### Problems the Paper Aims to Solve This paper aims to address the critical issues in the treatment of triple-negative breast cancer (TNBC). TNBC is a highly aggressive and heterogeneous subtype of breast cancer, currently lacking effective targeted therapies and mainly relying on chemotherapy. Therefore, finding new drugs and methods for TNBC treatment has significant clinical importance. ### Specific Research Content 1. **Background Introduction**: - Breast cancer is a major threat to women's health, especially TNBC, which has limited treatment options due to its high heterogeneity and aggressiveness. - Oxidative stress is prevalent in tumors, and excessive reactive oxygen species (ROS) can lead to cell apoptosis, DNA damage, etc., thereby exerting anti-tumor effects. 2. **Research Objectives**: - Synthesize a series of aflatoxin analogs and screen for compound D43, which has a significant inhibitory effect on TNBC cell proliferation. - Investigate the mechanisms of D43 on anti-proliferation, oxidative stress, apoptosis, and DNA damage in TNBC cells. 3. **Experimental Methods**: - **Cell Culture and Treatment**: Experiments were conducted using two TNBC cell lines, MDA-MB-231 and HCC1806. - **Compound Synthesis**: D43 was synthesized through chemical reactions. - **Cell Viability Assay**: SRB assay was used to detect cell viability. - **Colony Formation Assay**: Evaluated the impact of D43 on cell colony formation ability. - **DNA Synthesis Detection**: EdU labeling method was used to detect DNA synthesis. - **Cell Cycle Analysis**: PI staining and flow cytometry were used to analyze cell cycle changes. - **Apoptosis Analysis**: Annexin V/PI double staining method was used to detect cell apoptosis. - **ROS Level Detection**: DCFH-DA fluorescent probe was used to detect intracellular ROS levels. - **Immunofluorescence Staining**: Detected γ-H2AX foci to assess DNA damage. - **Animal Experiments**: Patient-derived organoids and xenograft models were used to verify the in vivo anti-tumor effects of D43. 4. **Main Findings**: - D43 significantly inhibited the proliferation of TNBC cells in a dose-dependent manner. - D43 induced DNA damage and apoptosis by increasing intracellular ROS levels. - D43 caused cell cycle arrest at the G2/M phase. - D43 showed significant tumor growth inhibition in patient-derived organoids and xenograft models, with good biosafety. ### Conclusion As a potential anti-cancer drug, D43 can effectively inhibit the proliferation of TNBC cells through multiple mechanisms, including increasing ROS levels, inducing DNA damage, and apoptosis. These findings provide new candidate drugs and research directions for the treatment of TNBC.

Toxoflavin analog D43 exerts antiproliferative effects on breast cancer by inducing ROS-mediated apoptosis and DNA damage

Inhibition of FEN1 Increases Arsenic Trioxide-Induced ROS Accumulation and Cell Death: Novel Therapeutic Potential for Triple Negative Breast Cancer

Apatinib-induced NF-κB Inactivation Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin.

Theaflavin-3, 3′-Digallate Induces Apoptosis and G2 Cell Cycle Arrest Through the Akt/MDM2/p53 Pathway in Cisplatin-Resistant Ovarian Cancer A2780/CP70 Cells

A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer

Coumarin-Furoxan Hybrid Suppressed the Proliferation and Metastasis of Triple-Negative Breast Cancer by Activating Mitochondrial Stress and Cell Apoptosis

Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage

Propofol Inhibits Proliferation and Augments the Anti-Tumor Effect of Doxorubicin and Paclitaxel Partly Through Promoting Ferroptosis in Triple-Negative Breast Cancer Cells

Phytoagent Deoxyelephantopin and Its Derivative Inhibit Triple Negative Breast Cancer Cell Activity through ROS-Mediated Exosomal Activity and Protein Functions

Ketoplatin in triple-negative breast cancer cells MDA-MB-231: High efficacy and low toxicity, and positive impact on inflammatory microenvironment

Discovery of fused benzimidazole-imidazole autophagic flux inhibitors for treatment of triple-negative breast cancer

F1012-2 Induced ROS-Mediated DNA Damage Response through Activation of MAPK Pathway in Triple-Negative Breast Cancer

Dihydroartemisinin-Transferrin Adducts Enhance TRAIL-Induced Apoptosis in Triple-Negative Breast Cancer in a P53-Independent and ROS-Dependent Manner

A Novel Derivative of Curcumol, HCL-23, Inhibits the Malignant Phenotype of Triple-Negative Breast Cancer and Induces Apoptosis and HO-1-Dependent Ferroptosis

Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2h,4h)-dione Analogues: Development of Potent Eef2k Degraders Against Triple-Negative Breast Cancer.

Actinomycin D Synergizes with Doxorubicin in Triple-Negative Breast Cancer by Inducing P53-dependent Cell Apoptosis.

Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer

Decreased Cell Proliferation with 2, 3‐ Dichloro‐5, 8‐Dimethoxy‐1, 4‐Naphthoquinone and 4‐Hydroxy Tamoxifen in Triple Negative Breast Cancer Cell Lines

Danggui Buxue Tang improves therapeutic efficacy of doxorubicin in triple negative breast cancer via ferroptosis

Ferroptosis-enhanced Chemotherapy for Triple-Negative Breast Cancer with Magnetic Composite Nanoparticles.

Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2 H,4 H)-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer